Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359093 | 0.91 | MEN1 (0.31) | HCRTR1HCRTR2ROCK2PRCP | |
| SCHEMBL1797801 | 0.89 | TRPV1 (0.38) | SCN9ASCN5AHCRTR1HCRTR2ROCK2 | |
| SCHEMBL1801613 | 0.85 | TRPV1 (0.41) | SCN9ASCN5APRCPRETTRPV1 | |
| SCHEMBL1796849 | 0.85 | TRPV1 (0.38) | SCN9ASCN5APRCPRETTRPV1 | |
| SCHEMBL12358862 | 0.84 | HCRTR1 (0.41) | HCRTR1HCRTR2ROCK2 | |
| SCHEMBL12358844 | 0.83 | SCN5A (0.40) | SCN9ASCN5A | |
| SCHEMBL1800044 | 0.83 | TRPV1 (0.43) | SCN9ASCN5ATRPV1 | |
| SCHEMBL1796434 | 0.83 | TRPV1 (0.41) | SCN9AHCRTR1HCRTR2PRCPTRPV1 | |
| SCHEMBL1796612 | 0.81 | TRPV1 (0.42) | SCN9ASCN5ATRPV1 | |
| SCHEMBL1793568 | 0.81 | TRPV1 (0.51) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | SCN9A 1573/4885SCN5A 1082/4885HCRTR1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.